TW225537B - - Google Patents

Info

Publication number
TW225537B
TW225537B TW081104702A TW81104702A TW225537B TW 225537 B TW225537 B TW 225537B TW 081104702 A TW081104702 A TW 081104702A TW 81104702 A TW81104702 A TW 81104702A TW 225537 B TW225537 B TW 225537B
Authority
TW
Taiwan
Application number
TW081104702A
Other languages
Chinese (zh)
Inventor
Weisenberger Johannes
Elke Seeke Seewaldt-Becker Frau
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Application granted granted Critical
Publication of TW225537B publication Critical patent/TW225537B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
TW081104702A 1991-07-27 1992-06-16 TW225537B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4124942A DE4124942A1 (de) 1991-07-27 1991-07-27 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
TW225537B true TW225537B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-06-21

Family

ID=6437152

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081104702A TW225537B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-07-27 1992-06-16

Country Status (16)

Country Link
US (1) US5463071A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0525629A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH05221999A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR930002344A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU652064B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2074685A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE4124942A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI923366L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT61747A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE922420A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL102638A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9204354A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO922940L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ243713A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW225537B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA925573B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940005271A (ko) * 1992-04-28 1994-03-21 디터 라우딘, 게르하르트 후버 표지된 피브리노겐 수용체 길항제, 이의 용도 및 이의 제조방법
DE4213919A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4213931A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4302051A1 (de) * 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
PT825184E (pt) * 1993-03-29 2001-11-30 Astrazeneca Ab Derivados heterociclicos como inibidores de agregacao de plaquetas
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
EP0690847A1 (en) * 1993-03-29 1996-01-10 Zeneca Limited Heterocyclic compounds as platelet aggregation inhibitors
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
ATE168106T1 (de) * 1993-11-24 1998-07-15 Du Pont Merck Pharma Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten
PT730590E (pt) * 1993-11-24 2001-05-31 Du Pont Pharm Co Derivados de isoxazolina e isoxazole como antagonistas dos reciptores do fibrinogenio
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
US5668165A (en) * 1995-06-07 1997-09-16 Scriptgen Pharmaceuticals, Inc. Small molecule inhibition of RNA/ligand binding
ZA966885B (en) * 1995-08-22 1998-02-16 Du Pont Merck Pharma Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
WO1997015567A1 (de) * 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
DE19605766A1 (de) * 1996-02-16 1997-08-21 Basf Ag Substituierte 2-Phenylpyridine
US6011052A (en) * 1996-04-30 2000-01-04 Warner-Lambert Company Pyrazolone derivatives as MCP-1 antagonists
WO1997049698A1 (en) * 1996-06-21 1997-12-31 Glaxo Group Limited Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
AR008245A1 (es) * 1996-06-21 1999-12-29 Glaxo Group Ltd Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
CA2263311A1 (en) * 1996-08-15 1998-02-19 Pasquale Nicholas Confalone Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
WO1998006694A1 (en) * 1996-08-16 1998-02-19 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6548512B1 (en) 1996-12-23 2003-04-15 Bristol-Myers Squibb Pharma Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
ZA9711586B (en) 1996-12-23 1999-07-01 Du Pont Merck Pharma Nitrogen containing heteroaromatics as factor Xa inhibitors.
AR012443A1 (es) * 1997-04-16 2000-10-18 Uriach & Cia Sa J Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos
ZA985251B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Inhibitors of factor Xa with a neutral P1 specificity group.
AU8150398A (en) * 1997-06-19 1999-01-04 Du Pont Pharmaceuticals Company Inhibitors of factor xa with a neutral p1 specificity group
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
JP2001524481A (ja) * 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
ES2230841T3 (es) 1998-03-27 2005-05-01 Bristol-Myers Squibb Pharma Company Pirazolinas y triazolinas disustituidas como inhibidores del factor xa.
US6348504B1 (en) 1999-03-30 2002-02-19 Richard E. Olson Oxime ethers as IIb/IIa antagonists
ES2197092T3 (es) 1999-04-02 2004-01-01 Bristol-Myers Squibb Pharma Company Sulfonil arilos como inhibidores del factor xa.
EP1218376B1 (en) 1999-09-10 2005-11-09 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60208792T2 (de) 2001-06-22 2006-08-31 Merck & Co., Inc. Tyrosin-kinase inhibitoren
CA2462000A1 (en) * 2001-10-09 2003-04-17 3-Dimensional Pharmaceuticals, Inc. Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
MXPA04008901A (es) * 2002-03-13 2004-11-26 Euro Celtique Sa Pirimidinas arilo sustituidas y el uso de las mismas.
US6872724B2 (en) * 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US20040023978A1 (en) * 2002-07-24 2004-02-05 Yu Ren Active salt forms with tyrosine kinase activity
US20040023981A1 (en) * 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
NZ537980A (en) * 2002-08-23 2007-08-31 Rigel Pharmaceuticals Inc Pyridyl substituted heterocycles useful for treating or preventing HCV infection
US7326790B2 (en) * 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7115642B2 (en) 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
US7220745B2 (en) * 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
WO2005097760A1 (en) * 2004-03-26 2005-10-20 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
MXPA06012130A (es) * 2004-04-20 2007-01-31 Transtech Pharma Inc Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina.
BRPI0515499A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de piridina para a inibição de estearoil-coa-desaturase humana
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
EP2266569A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AR051202A1 (es) * 2004-09-20 2006-12-27 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP2269610A3 (en) * 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626148A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) * 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
WO2006034338A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
CN101084211A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
AP2007004047A0 (en) * 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
CN101203498A (zh) * 2005-05-02 2008-06-18 里格尔药品股份有限公司 包括可代谢部分的杂环抗病毒化合物及其用途
JP2009513563A (ja) * 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
CA2731442A1 (en) * 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
US10252984B2 (en) * 2011-10-27 2019-04-09 Mayo Foundation For Medical Education And Research Inhibiting G protein coupled receptor 6 kinase polypeptides
WO2013187496A1 (ja) 2012-06-15 2013-12-19 田辺三菱製薬株式会社 芳香族複素環化合物
HRP20220522T1 (hr) 2014-08-04 2022-06-10 Nuevolution A/S Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
WO2017205459A1 (en) 2016-05-26 2017-11-30 Kalyra Pharmaceuticals, Inc. Egfr inhibitor compounds
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
EP4392422A1 (en) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2023028238A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3792170A (en) * 1972-03-14 1974-02-12 Merck & Co Inc Novel alkylsulfinyl derivatives for pain,fever and inflammation
DE3486009T2 (de) * 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
US4820722A (en) * 1987-08-14 1989-04-11 Eli Lilly And Company Disubstituted tetrazoles and their use as leukotriene antagonists
US4820723A (en) * 1987-08-14 1989-04-11 Eli Lilly And Company Disubstituted tetrazole leukotriene antagonists and methods for their use thereas
GB8725260D0 (en) * 1987-10-28 1987-12-02 Lilly Industries Ltd Organic compounds
US5081127A (en) * 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
EP0440183A1 (en) * 1990-02-01 1991-08-07 Takeda Chemical Industries, Ltd. Oxazole compounds, their production and use
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4107857A1 (de) * 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
HUT61747A (en) 1993-03-01
FI923366A7 (fi) 1993-01-28
JPH05221999A (ja) 1993-08-31
EP0525629A3 (en) 1997-03-19
MX9204354A (es) 1993-01-01
NO922940L (no) 1993-01-28
FI923366A0 (fi) 1992-07-24
IL102638A0 (en) 1993-01-14
FI923366L (fi) 1993-01-28
CA2074685A1 (en) 1993-01-28
IL102638A (en) 1996-10-16
US5463071A (en) 1995-10-31
IE922420A1 (en) 1993-01-27
DE4124942A1 (de) 1993-01-28
EP0525629A2 (de) 1993-02-03
ZA925573B (en) 1994-01-24
NO922940D0 (no) 1992-07-24
AU652064B2 (en) 1994-08-11
HU9202450D0 (en) 1992-10-28
AU2056992A (en) 1993-01-28
NZ243713A (en) 1995-06-27
KR930002344A (ko) 1993-02-23

Similar Documents

Publication Publication Date Title
TW225537B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0497252A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0498143T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0499986A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2673333B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2673641B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0549891T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0549782T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK33591D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0545490T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE4292011T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2672693B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91526U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK132791D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSDI910045S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPH0498890U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPH04100309U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK197691D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN177372B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91556U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91536U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91539U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU7834891A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91549U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ECSM91550U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)